{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cai L"],"funding":["Augusta University","NCI NIH HHS","National Institutes of Health"],"pagination":["607"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7196607"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11"],"pubmed_abstract":["Autologous T cells engineered with T receptor genes (TCR) are being studied to treat cancers. We have recently identified a panel of mouse TCRs specific for the HLA-A0201/alpha fetoprotein epitope (AFP<sub>158</sub>) complex and have shown that human T cells engineered with these TCR genes (TCR-Ts) can eradicate hepatocellular carcinoma (HCC) xenografts in NSG mice. However, due to TCR's promiscuity, their off-target cross-reactivity must be studied prior to conducting clinical trials. In this study, we conducted <i>in vitro</i> X-scan assay and <i>in silico</i> analysis to determine the off-target cross-reactivity of 3 AFP<sub>158</sub>-specific TCR-Ts. We found that the 3 AFP<sub>158</sub>-specific TCR-Ts could be cross-activated by ENPP1<sub>436</sub> peptide and that the TCR3-Ts could "],"journal":["Frontiers in immunology"],"pubmed_title":["Preclinical Studies of the Off-Target Reactivity of AFP<sub>158</sub>-Specific TCR Engineered T Cells."],"pmcid":["PMC7196607"],"funding_grant_id":["R01 CA235159"],"pubmed_authors":["Caraballo Galva LD","Peng Y","Yao Y","He Y","Cai L","Luo X","Zhu W","Ji Y"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical Studies of the Off-Target Reactivity of AFP<sub>158</sub>-Specific TCR Engineered T Cells.","description":"Autologous T cells engineered with T receptor genes (TCR) are being studied to treat cancers. We have recently identified a panel of mouse TCRs specific for the HLA-A0201/alpha fetoprotein epitope (AFP<sub>158</sub>) complex and have shown that human T cells engineered with these TCR genes (TCR-Ts) can eradicate hepatocellular carcinoma (HCC) xenografts in NSG mice. However, due to TCR's promiscuity, their off-target cross-reactivity must be studied prior to conducting clinical trials. In this study, we conducted <i>in vitro</i> X-scan assay and <i>in silico</i> analysis to determine the off-target cross-reactivity of 3 AFP<sub>158</sub>-specific TCR-Ts. We found that the 3 AFP<sub>158</sub>-specific TCR-Ts could be cross-activated by ENPP1<sub>436</sub> peptide and that the TCR3-Ts could ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-04-18T07:29:18.407Z","creation":"2020-05-22T19:58:29Z"},"accession":"S-EPMC7196607","cross_references":{"pubmed":["32395117"],"doi":["10.3389/fimmu.2020.00607"]}}